UCLA receives $10 million to launch Howard and Irene Levine Family Center for Movement Disorders
Key takeawaysThe Howard and Irene Levine Family Foundation will provide the resources to endow four chairs and a research fund in the UCLA Department of Neurology to support basic research science on Parkinson ’s disease.The donations are meant to honor Dr. Jeff Bronstein, director of the UCLA Movement Disorders Program and Clinic.In addition to their medical philanthropy, Howard and Irene Levine have been dedicated supporters of the UCLA Anderson School of Management and its Ziman Center for Real Estate.Donations totaling $10 million from longtime UCLA supporters Howard and Irene Levine and their family foundation wil...
Source: UCLA Newsroom: Health Sciences - February 26, 2024 Category: Universities & Medical Training Source Type: news
Medicines for four rare diseases become cheaper due to domestic production
Drugs for four of these diseases -Tyrosinemia Type 1, Gaucher's Disease, Wilson's Disease and Dravet-Lennox Gastaut Syndrome - along with sickle cell Anemia have been approved and are being manufactured indigenously. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - November 25, 2023 Category: Pharmaceuticals Source Type: news
Pushing the boundaries of treatment for Wilson disease
In a Q&A, Yale Dr. Uyen To discusses her path toward research on a rare genetic disorder that causes excess copper accumulation in the body. (Source: Yale Science and Health News)
Source: Yale Science and Health News - May 10, 2023 Category: Universities & Medical Training Source Type: news
TETA4 Noninferior to Penicillamine for Stable Wilson's Disease
(MedPage Today) -- Oral maintenance therapy with trientine tetrahydrochloride (TETA4; Cuvrior) was noninferior to penicillamine for patients with stable Wilson's disease, the phase III randomized CHELATE trial showed.
In an intention-to-treat... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 3, 2022 Category: Gastroenterology Source Type: news
FDA Approves New Drug for Wilson's Disease FDA Approves New Drug for Wilson's Disease
Trientine tetrahydrochloride (Cuvrior) is approved to treat adults with stable Wilson ' s disease who are decoppered and tolerant to penicillamine.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 4, 2022 Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news
First Drug Approved for Wilson's Disease in Decades
(MedPage Today) -- The FDA approved oral trientine tetrahydrochloride (Cuvrior) for the treatment of adults with stable Wilson's disease who are de-coppered and tolerant to penicillamine, drugmaker Orphalan announced on Monday.
Wilson's disease... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - May 3, 2022 Category: Gastroenterology Source Type: news
What is in the Differential Diagnosis for Green, Blue or Violet Skin Conditions?
Discussion
Acrocyanosis is commonly seen in the newborn period as the baby transitions to extra-uterine life. It appears as blue-purple coloration of the distal extremities which usually improves over several hours.
Blue melanocytosis is also a common normal variant of skin color. It usually is seen on the posterior surface of the body around the spine and buttocks, but can also be on the upper parts of the extremities.
It is a blue-black coloration that shows a normal skin undertone when palpated.
This is the second in a short case series of differential diagnoses of colored skin conditions.
An introduction to dermatologi...
Source: PediatricEducation.org - May 2, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
VTX-801 receives U.S. FDA Fast Track designation for the treatment of Wilson Disease
Vivet Therapeutics ("Vivet"), a clinical-stage biotechnology company, and Pfizer Inc. (NYSE: PFE) announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VTX-801, Vivet's clinical-stage gene therapy for the treatment of Wilson Disease - a rare, genetic disorder that reduces the ability of the liver and other tissues to regulate copper levels, causing severe hepatic damage, neurological symptoms, and potentially death. (Source: World Pharma News)
Source: World Pharma News - August 13, 2021 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
Lupin launches generic drug to treat Wilson's disease in US market
The Mumbai-based drug firm's product is the generic equivalent of Mylan Specialty's Depen tablets, which are indicated for the treatment of Wilson's disease, Cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - March 2, 2021 Category: Pharmaceuticals Source Type: news
5 facts about Wilson Disease
Yale ’s Dr. Michael Schilsky, an expert on Wilson Disease, shares critical information about the rare, hereditary liver disorder. (Source: Yale Science and Health News)
Source: Yale Science and Health News - February 2, 2021 Category: Universities & Medical Training Source Type: news
Pfizer buys stake in French gene company in deal worth up to $636M
Pfizer Inc. said it's buying a stake in a French gene company in a deal that could be worth up to $636 million.
The New York drug company (NYSE: PFE) said it's paying $51 million upfront to acquire a 15 percent stake in Vivet Therapeutics of Paris.
Vivet is working on a drug — VTX-801 — to treat Wilson disease, which is a rare and possibly fatal condition in which excess copper collects in the body's l iver and other organs, perhaps to life-threatening levels.
“VTX-801 could provide a potentially… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 21, 2019 Category: Biotechnology Authors: Ben Miller Source Type: news
Pfizer buys stake in French gene company in deal worth up to $636M
Pfizer Inc. said it's buying a stake in a French gene company in a deal that could be worth up to $636 million.
The New York drug company (NYSE: PFE) said it's paying $51 million upfront to acquire a 15 percent stake in Vivet Therapeutics of Paris.
Vivet is working on a drug — VTX-801 — to treat Wilson disease, which is a rare and possibly fatal condition in which excess copper collects in the body's l iver and other organs, perhaps to life-threatening levels.
“VTX-801 could provide a potentially… (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - March 21, 2019 Category: Health Management Authors: Ben Miller Source Type: news
Wilson Disease: Overview Video Wilson Disease: Overview Video
This video covers the pathophysiology of Wilson disease, as well as common signs and symptoms, complications, and treatments.Osmosis (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 28, 2019 Category: Pathology Tags: Med Students Commentary Source Type: news
Copper-reducing molecule could help against Wilson's disease
A compound developed in preclinical experiments is showing promise in treating disorders with high levels of copper, including Wilson's disease. (Source: Health News - UPI.com)
Source: Health News - UPI.com - June 27, 2018 Category: Consumer Health News Source Type: news
Progress toward improved Wilson's disease drug
(Cold Spring Harbor Laboratory) Researchers at CSHL, working in collaboration with DepYmed Inc., a CSHL spinout company, today report that they have conducted promising preclinical experiments on a compound that could be used to treat Wilson's disease and possibly other disorders -- including certain types of cancer -- in which levels of copper in the body are elevated, causing or contributing to pathology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 26, 2018 Category: International Medicine & Public Health Source Type: news
